Baxter International, Inc. Submits Application For FDA Approval Of OBI-1 For Patients With Acquired Hemophilia A
Published: Dec 10, 2013
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today announced that the company has submitted a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for the approval of OBI-1, a recombinant antihemophilic porcine sequence factor VIII, in patients with acquired hemophilia A. Phase 2/3 data supporting the submission were presented at the American Society of Hematology’s (ASH) 55th Annual Meeting in New Orleans, LA.
Help employers find you! Check out all the jobs and post your resume.